You don't have javascript enabled. Good luck with that.
Skip to content

FOR US HEALTHCARE PROFESSIONALS

Adbry is strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2

How Adbry Works

A targeted approach neutralize IL-13 with Adbry3,4

AS LITTLE AS $0

For eligible patientsa

With Copay
Savings

IL-13 Signaling

In atopic dermatitis, IL-13
signaling is a key driver of
dysregulated immune response5

In chronic atopic dermatitis:

 

  • IL-13 is overexpressed in both lesional and
    nonlesional skin6

  • Overexpression of IL-13 contributes to the
    vicious cycle of inflammation, microbiome dysbiosis,
    pruritus, and skin-barrier dysfunction5,7

  • Expression of IL-13 in skin correlates with increased
    disease severity6,8
Steps towards IL-13 signaling including inflammation/immune dysregulation, microbiome dysbiosis, pruritus, and barrier dysfunction.

Chronic, underlying inflammation in atopic dermatitis requires a long-term treatment approach9,10

Adbry is the first fully human, high-affinity monoclonal antibody IL-13 inhibitor3,4

  • Adbry leaves the natural function of the decoy receptor intact3
  • Adbry is a fully human IgG4 monoclonal antibody that specifically binds to human IL-13, a naturally occurring cytokine of the type II immune response, and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).3
  • Adbry selectively inhibits IL-13 interaction with the type II receptor complex (IL-13Rα1/IL-4Rα), preventing IL-13–induced inflammatory responses in the skin.3
How IL-13 targeting works via Adbry® (tralokinumab-idrm).

Adbry is not an immunosuppressant or steroid. There is no requirement for initial lab testing or ongoing lab monitoring in the Prescribing Information.

Adbry Mechanism of Action
Adbry mechanism of action video thumbnail

Watch the Adbry MOA Video

View
Efficacy

See Efficacy Data

View Safety
Data

View Coverage